The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...

The drug is groundbreaking, potentially eliminating the need for a long-sought-after HIV vaccine. In her own words: Anne ...

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.